SCC
ZVSA

Spring Creek Capital’s ZyVersa Therapeutics ZVSA Stock Holding History

Spring Creek Capital’s Portfolio ZVSA Stock Details ZVSA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-1,000
Closed -$3.47M – 79
2022
Q1 		$3.47M Buy
+1,000
New +$3.46M 0.14% 155

Other funds holding ZVSA

CM
Cohanzick Management Pleasantville, New York $231K AUM 3.17% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return
RA
RiverPark Advisors New York $276M AUM 15.54% 1-Year Est. Return
SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $4.33B AUM 1.35% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return
KL
KIM LLC Wichita, Kansas $976M AUM 0.91% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return

Spring Creek Capital's ZVSA Position: Q2 2022 in Review

Spring Creek Capital sold out of ZyVersa Therapeutics (ZVSA) in Q2 2022, closing a stake of 1,000 shares — an estimated $3.47M sold.

Spring Creek Capital first reported a position in ZVSA in Q1 2022 and held it in 1 quarter. The position peaked at $3.47M in Q1 2022. 24 funds tracked by Wall St. Rank hold ZVSA as of Q2 2022.

  • Spring Creek Capital reported no remaining ZyVersa Therapeutics position as of Q2 2022 after selling out during the quarter.
  • Spring Creek Capital sold 1,000 ZyVersa Therapeutics shares in Q2 2022, an estimated $3.47M.
  • Spring Creek Capital first reported a position in ZyVersa Therapeutics in Q1 2022 and held it in 1 quarter.
  • Spring Creek Capital's ZyVersa Therapeutics position peaked at $3.47M in Q1 2022.
  • 24 funds tracked by Wall St. Rank held ZyVersa Therapeutics as of Q2 2022.

Based on Spring Creek Capital's 13F filing for Q2 2022.